<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; down</title>
	<atom:link href="http://www.tapanray.in/tag/down/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Tipping Point For Robust Healthcare System In India</title>
		<link>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-tipping-point-for-robust-healthcare-system-in-india</link>
		<comments>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/#comments</comments>
		<pubDate>Sun, 19 Nov 2017 23:32:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[accelerated]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[bottom]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[point]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tipping]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8558</guid>
		<description><![CDATA[“Given the popular uptake of universal health coverage reforms elsewhere in Asia, the Feb 4 elections may be a tipping point for health in India. For example, in 2012, Joko Widodo was elected Governor of Jakarta. He launched popular UHC &#8230; <a href="http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Managing Pharma Investors’ Expectations When The Chips Are Down</title>
		<link>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=managing-pharma-investors-expectations-when-the-chips-are-down</link>
		<comments>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/#comments</comments>
		<pubDate>Sun, 18 Jun 2017 23:34:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[activist]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chips]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Investors]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8282</guid>
		<description><![CDATA[Triggered by several critical factors, over a relatively short period of time, a downward spiral is visible with most Indian Pharma stocks, with a significant erosion in market capitalization of many large players in the country. A set of important &#8230; <a href="http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Global Generic Drug Market Slowing Down?</title>
		<link>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-global-generic-drug-market-slowing-down</link>
		<comments>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/#comments</comments>
		<pubDate>Sun, 04 Jun 2017 23:55:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[elf]]></category>
		<category><![CDATA[expiration]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inflicted]]></category>
		<category><![CDATA[injury]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[murmurs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[slowing]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8258</guid>
		<description><![CDATA[Driven by a strong environmental headwind, both within and outside the country, several pharma companies in India have recently started raising a red flag on their future earning guidance for the stock market, though citing quite different reasons altogether. Quoting &#8230; <a href="http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-global-generic-drug-market-slowing-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Humongous Pharma Corruption: China Ups The Ante&#8230;and India?</title>
		<link>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=humongous-pharma-corruption-china-ups-the-ante-and-india</link>
		<comments>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/#comments</comments>
		<pubDate>Mon, 23 Sep 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alcon]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[Apco]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[behind]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[biopharmaceuticals]]></category>
		<category><![CDATA[bribers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[chases]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[conducts]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[crack]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[Gan]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Lee]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reasons]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[remain]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[SG&A]]></category>
		<category><![CDATA[Sino]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[Values]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3696</guid>
		<description><![CDATA[In the &#8216;pharma bribery&#8217; related scandal in China, many postulated that the Chinese Government has cracked down selectively on Multinational Corporations (MNCs) to extend unfair business advantages for its local players. Media reports of September 2013 indicate that in all &#8230; <a href="http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/humongous-pharma-corruption-china-ups-the-ante-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
